ArticleJournal of translational autoimmunity2021
Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies.
Article in Journal of translational autoimmunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency.Journal of clinical immunology · 2023Pooled it
- Pathogen spectrum and immunotherapy in patients with anti-IFN-γ autoantibodies: A multicenter retrospective study and systematic review.Frontiers in immunology · 2022Pooled it
- Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti-IFN-γ Immunodeficiency.JAMA network open · 2026Article
- Clinical course and outcomes of patients with anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency: an observational cohort study.Annals of medicine · 2025Observational
- Clinical spectrum of Talaromyces marneffei infections in HIV-negative patients: an 18-case series including a rare presentation with gastrointestinal onset, adrenal mass, and hemophagocytic lymphohistiocytosis.BMC infectious diseases · 2025Article
- Disseminated talaromycosis in HIV-negative patients with lung cancer: a rare case report and literature review.BMC infectious diseases · 2025Review
- A patient with positive anti-IFN-γ autoantibody and monoclonal gammaglobulinemia masquerading as multiple myeloma: Case report and literature review.Clinical case reports · 2024Article
- Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Case report: Systemic multi-organ involvement in an adult-onset immunodeficiency patient infected withFrontiers in immunology · 2024Article
- Anticytokine Autoantibodies in Infectious Diseases: A Practical Overview.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to reduce autoantibodies leading to clinical and radiographic improvement in infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.